 |
|
Chemoreduction With Topical Mitomycin C Prior to Resection of Extensive Squamous Cell Carcinoma of the Conjunctiva
Arch Ophthalmol. 2005;123:109-113.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Topical mitomycin C (MMC) is effective for treatment of superficial or invasive squamous cell carcinoma (SCC) of the conjunctiva.1-11 In most instances, the chemotherapy agent is delivered 4 times daily in topical eyedrop form directly on the affected ocular surface. The medication is continued generally for 3 or 4 weeks, at which time the tumor is usually completely regressed.
Published results have shown that thin tumors, typically those that are less than 4 mm in thickness, show complete regression with MMC.1-8 Complete regression can be found with thin tumors even if they are extensive over most of the conjunctival and corneal surface.8 Thick tumors ( 4 mm in thickness), however, may show only partial regression with MMC, and there is the temptation to continue the medication for a prolonged period. Nevertheless, some patients do not show a complete response despite several chemotherapy cycles, and in such cases, prolonged therapy with . . . [Full Text of this Article] Report of Cases
Case 1 Case 2 Case 3
Comment
AUTHOR INFORMATION
Carol L. Shields, MD;
Hakan Demirci, MD;
Brian P. Marr, MD;
Arman Masheyekhi, MD;
Miguel Materin, MD;
Jerry A. Shields, MD
|
